Y-mAbs Reports MAA Submission to EMA for Omburtamab to Treat Pediatric Patients with CNS/Leptomeningeal Metastasis from Neuroblastoma

 Y-mAbs Reports MAA Submission to EMA for Omburtamab to Treat Pediatric Patients with CNS/Leptomeningeal Metastasis from Neuroblastoma

Y-mAbs Reports MAA Submission to EMA for Omburtamab to Treat Pediatric Patients with CNS/Leptomeningeal Metastasis from Neuroblastoma

Shots:

  • The company has submitted MAA for Omburtamab to EMA for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma
  • The company continues to advance the Omburtamab program addressing the unmet medical need globally and work closely with FDA to resubmit the BLA in Q2 or Q3’21
  • Y-mAbs get an exclusive license from MSK while MSK has an institutional financial interest related to the compound and Y-mAbs. Omburtamab is mAb targeting B7-H3 and is radiolabeled before intraventricular CNS administration

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Y-mabs

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post